Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 3
1990 5
1991 5
1992 8
1993 8
1994 11
1995 10
1996 13
1997 12
1998 12
1999 13
2000 12
2001 19
2002 15
2003 19
2004 16
2005 15
2006 25
2007 20
2008 26
2009 27
2010 22
2011 23
2012 24
2013 29
2014 31
2015 26
2016 27
2017 26
2018 34
2019 35
2020 10
Text availability
Article attribute
Article type
Publication date

Search Results

526 results
Results by year
Filters applied: . Clear all
Page 1
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, Schliemann C, Bohnenberger H, Angenendt L, Hartmann W, Wardelmann E, Rothenburger T, Mohr S, Scheich S, Comoglio F, Wilke A, Ströbel P, Serve H, Michaelis M, Ferreirós N, Geisslinger G, Xiong Y, Keppler OT, Cinatl J Jr. Oellerich T, et al. Among authors: Geisslinger G. Nat Commun. 2019 Aug 2;10(1):3475. doi: 10.1038/s41467-019-11413-4. Nat Commun. 2019. PMID: 31375673 Free PMC article.
Ceramides as Novel Disease Biomarkers.
Kurz J, Parnham MJ, Geisslinger G, Schiffmann S. Kurz J, et al. Among authors: Geisslinger G. Trends Mol Med. 2019 Jan;25(1):20-32. doi: 10.1016/j.molmed.2018.10.009. Epub 2018 Nov 23. Trends Mol Med. 2019. PMID: 30477968 Review.
Novel Approaches to Persistent Pain Therapy.
Sisignano M, Parnham MJ, Geisslinger G. Sisignano M, et al. Among authors: Geisslinger G. Trends Pharmacol Sci. 2019 Jun;40(6):367-377. doi: 10.1016/j.tips.2019.04.003. Epub 2019 May 8. Trends Pharmacol Sci. 2019. PMID: 31078322 Review.
Sphingosine-1-phosphate (S1P) induces potent anti-inflammatory effects in vitro and in vivo by S1P receptor 4-mediated suppression of 5-lipoxygenase activity.
Fettel J, Kühn B, Guillen NA, Sürün D, Peters M, Bauer R, Angioni C, Geisslinger G, Schnütgen F, Meyer Zu Heringdorf D, Werz O, Meybohm P, Zacharowski K, Steinhilber D, Roos J, Maier TJ. Fettel J, et al. Among authors: Geisslinger G. FASEB J. 2019 Feb;33(2):1711-1726. doi: 10.1096/fj.201800221R. Epub 2018 Sep 6. FASEB J. 2019. PMID: 30188757
Pharmacokinetics of non-intravenous formulations of fentanyl.
Lötsch J, Walter C, Parnham MJ, Oertel BG, Geisslinger G. Lötsch J, et al. Among authors: Geisslinger G. Clin Pharmacokinet. 2013 Jan;52(1):23-36. doi: 10.1007/s40262-012-0016-7. Clin Pharmacokinet. 2013. PMID: 23100195 Review.
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr. Schneider C, et al. Among authors: Geisslinger G. Nat Med. 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255. Epub 2016 Dec 19. Nat Med. 2017. PMID: 27991919
Activation of AMPK and its Impact on Exercise Capacity.
Niederberger E, King TS, Russe OQ, Geisslinger G. Niederberger E, et al. Among authors: Geisslinger G. Sports Med. 2015 Nov;45(11):1497-509. doi: 10.1007/s40279-015-0366-z. Sports Med. 2015. PMID: 26186961 Review.
The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.
Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, Tofoleanu F, Reiss K, Ferreirós N, Geisslinger G, Batista VS, Ji X, Cinatl J Jr, Keppler OT, Xiong Y. Knecht KM, et al. Among authors: Geisslinger G. Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):E10022-E10031. doi: 10.1073/pnas.1805593115. Epub 2018 Oct 10. Proc Natl Acad Sci U S A. 2018. PMID: 30305425 Free PMC article.
526 results
Jump to page
Feedback